博安生物(06955.HK)擬配售2665.56萬股 總籌2.53億港元
格隆匯7月31日丨博安生物(06955.HK)發佈公吿,2024年7月30日,公司及配售代理(即瑞銀集團及安信國際)訂立配售協議,據此,配售代理同意作為公司的代理,按個別基準(並非共同,亦非與另一配售代理共同及個別)促使買方按配售價竭誠購買配售股份,惟須遵守配售協議所載條款及受當中所載條件規限。
可能根據配售事項出售的配售股份總數為2665.56萬股,相當於本公吿日期的已發行股份總數約5.23%;及經配發及發行配售股份擴大的已發行股份總數約4.97%。配售價每股9.50港元較股份於最後交易日在聯交所所報收市價每股9.79港元折讓約2.96%。
假設總計2665.56萬股配售股份將獲出售,配售事項所得款項總額預期將為約2.532億港元。預期配售事項所得款項淨額約為2.499億港元。公司擬將配售事項的所得款項淨額用作以下用途:(a)約50%將用於:(i)BA1104在中國的3期臨牀試驗及上市註冊;(ii)地舒單抗注射液(BA6101和BA1102)在歐洲、美國、日本的國際多中心3期臨牀試驗及上市註冊;及(iii)各種創新候選產品的臨牀試驗的研發;(b)約20%將用於博優諾、博優倍及博洛加的商業化;及(c)約30%將用於補充公司營運資金及一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.